1 | 2-mercaptobenzothiazole | - | - |
- |
- |
212 [1] 212 💬 |
2 | Ascorbic acid | 2l polyethylene glycol/ascorbic acid [5] 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid (vitamin c) and alpha-tocopherol (vitamin e); Ascorbic acid vit c; | [1] D00018 D00018 💬 |
- |
- |
010 [8] 10, 97, 192, 206, 210, 211, 212, 298 💬 |
3 | Bosentan | Bosentan [18] Bosentan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan administration; Bosentan and sildenafil; Bosentan group; Bosentan monohidrato; Bosentan monohydrat; Bosentan monohydrate; Bosentan mylan; Bosentan, ambrisentan; Device: nirs after bosentan administration; Device: tcd after bosentan administration; Duo-therapy with sildenafil + bosentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil 20mg and bosentan 62.5mg; Sildenafil singly or in association with bosentan; | [2] D01227 D01227
D07538 D07538 💬 |
[2] EDNRA, EDNRB 💬 |
Calcium signaling pathway [9] Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 [11] 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬 |
4 | Dexmedetomidine | Dexmedetomidine [10] Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; Dexmedetomidine with ropivacaine; Fentanyl (low dose) + dexmedetomidine; Scopolamine, atropine, edaravone and dexmedetomidine; | [2] D00514 D00514
D01205 D01205 💬 |
[3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 [12] 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
5 | Liothyronine | Liothyronine [3] Liothyronine; Liothyronine i 131; Liothyronine sodium; | [2] D01011 D01011
D08128 D08128 💬 |
[2] THRA, THRB 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
013 [4] 13, 78, 210, 212 💬 |
6 | Liothyronine I-131 | - | - |
- |
- |
210 [2] 210, 212 💬 |
7 | Sildenafil | 20 mg sildenafil citrate by mouth [32] 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Bosentan and sildenafil; Duo-therapy with sildenafil + bosentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); G04be03- sildenafil - sildenafil (citrato); Mono-therapy with sildenafil; Oral sildenafil; Other: standard of care sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (acute-1 hour); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil (subchronic-4 weeks); Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil by injection; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil filmtabletten; Sildenafil singly or in association with bosentan; Sildenafil therapy; Sildenafilo; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Tadalafil and sildenafil; | [2] D02229 D02229
D08514 D08514 💬 |
[1] PDE5A 💬 |
Metabolic pathways [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 [17] 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |